Ulcerative Colitis Treatment & Management
- Author: Marc D Basson, MD, PhD, MBA, FACS; Chief Editor: BS Anand, MD more...
The treatment of ulcerative colitis relies on initial medical management with corticosteroids and anti-inflammatory agents, such as sulfasalazine, in conjunction with symptomatic treatment with antidiarrheal agents and rehydration. Surgery is contemplated when medical treatment fails or when a surgical emergency (eg, perforation of the colon) occurs. Surgical options include total colectomy (panproctocolectomy) and ileostomy, total colectomy, and ileoanal pouch reconstruction or ileorectal anastomosis. In an emergency situation, subtotal colectomy with end-ileostomy is recommended.[4, 5, 6]
Chronic ulcerative colitis is associated with an increase in the risk of carcinoma, and colonic carcinoma may easily be missed in the setting of ulcerative colitis. Patients with ulcerative colitis must be made aware of the significant risk of colon cancer, and surgical intervention in nonacute cases should be encouraged after 10 years of disease or when symptoms are refractory or steroid dependent. Indications for surgery in ulcerative colitis vary and are discussed in detail in Surgical Treatment.
As yet, no evidence suggests that regular endoscopic screening of patients with ulcerative colitis improves survival. However, the current standard of practice by many gastroenterologists is to continue screening these patients at regular intervals, owing to the risk of cancer development and possible legal implications if it is not detected.
Consultations include a gastroenterologist, as well as a surgeon for severe or fulminant colitis.
Treatment of Mild Disease
In mild disease confined to the rectum, topical mesalazine (Asacol) given by suppository is the preferred therapy. Enemas and foams are less effective because their concentration in the rectum rapidly diminishes. Left-sided colonic disease is best treated with a combination of mesalazine suppository and an oral aminosalicylate. Combined oral and topical therapy is better than either route alone. Of the oral amino salicylates, sulfasalazine has the longest history. Sulfasalazine is 5-aminosalicylate (5-ASA) coupled to a sulfapyridine. It is poorly absorbed in the proximal bowel, and the bacteria in the colon uncouple the 5-ASA from the sulfa moiety, allowing 5-ASA to exert its anti-inflammatory effect on the colonic mucosa by inhibiting prostaglandin synthesis.
Mesalazine, another 5-ASA-containing molecule, is better tolerated orally than sulfasalazine and has become the preferred medication. A meta-analysis previously suggested that doses of at least 2 g per day are more effective in inducing remission and preventing relapse, but that exceeding 2.5 g per day might not have any additional benefit. However, more recent studies have shown that higher doses are beneficial in patients not responding to lower doses (eg, 2.4 g vs 4.8 g). [50, 51]
After remission, long-term maintenance therapy is encouraged, but compliance rates are low. One systematic review analyzed the outcomes of once-daily dosing of mesalazine compared to a conventional dosing schedule (minimum of b.i.d). It was concluded that once-daily dosing is as effective as divided dosing for relapse prevention, and such daily dosing may increase compliance, although this has not been formally evaluated.[52, 53]
Systemic steroids are indicated when disease fails to quickly respond to aminosalicylates.
In January 2013, the US Food and Drug Administration (FDA) approved an extended-release oral formulation of budesonide for the treatment of active mild-to-moderate ulcerative colitis in adults patients. Because budesonide is a potent corticosteroid that exerts only minimal systemic activity, this formulation provides the benefit of a powerful anti-inflammatory drug delivered locally while avoiding many of the systemic side effects associated with systemic steroids.
In a pooled analysis of efficacy and safety outcomes from two phase 3 studies of budesonide MMX 9 mg and 6 mg and placebo in 672 patients with mild-to-moderate ulcerative colitis, Sandborn and colleagues found that budesonide MMX 9 mg was safe, efficacious, and well tolerated for inducing remission of mild-to-moderate disease. The budesonide MMX 9 mg resulted in significantly greater combined clinical and colonoscopic remission rates compared with placebo, whereas the budesonide MMX 6 mg did not. Symptom resolution and colonoscopic improvement rates were also significantly greater with budesonide MMX 9 mg compared with placebo.
Budesonide rectal foam was approved in October 2014 and is indicated for the induction of remission in adults with active mild-to-moderate distal ulcerative colitis extending up to 40 cm from the anal verge. Approval was based on 2 randomized, placebo-controlled trials (n=546) that showed that more participants who received the budesonide rectal foam achieved remission and a rectal bleeding score of 0 at 6 weeks of therapy than placebo.
Treatment of Acute, Severe Disease
Acute, severe ulcerative colitis (ie, >6 bloody bowel movements/d, with one of the following: fever >38°C, hemoglobin level < 10.5 g/dL, heart rate >90 bpm, erythrocyte sedimentation rate >30 mm/h, or C-reactive protein level >30) requires hospitalization and treatment with intravenous high-dose corticosteroids (hydrocortisone 400 mg/d or methylprednisolone 60 mg/d). A meta-analysis supports the use of glucocorticosteroids in inducing remission in acute severe ulcerative colitis.
Alternative induction medications have been evaluated. Cyclosporine,tacrolimus, infliximab, adalimumab, and golimumab are often effective in bringing steroid-resistant disease under control. Infliximab has shown to be superior to placebo in inducing remission of moderate-to-severe ulcerative colitis. These agents have not been compared in a randomized, controlled fashion, and therefore, one drug cannot be recommended over the others. They have all been associated with overwhelming sepsis. Cyclosporine and tacrolimus are both nephrotoxic and should not be used for long-term therapy. Infliximab requires the coadministration of an antimetabolite to limit the development of human anti-mouse antibody (HAMA).
In the Active Ulcerative Colitis Trial (ACT)-1 and ACT-2, colectomy incidence was found to be 10% for the infliximab group, as compared to 17% for the placebo group through 54 weeks, and additional benefits of infliximab included fewer colitis-related hospitalizations and surgeries/procedures. In these 2 randomized, double-blind, placebo-controlled trials, the benefit of infliximab induction and maintenance therapy in moderate to severe ulcerative colitis was demonstrated in 728 patients.
Adalimumab was approved by the FDA in September 2012 for ulcerative colitis unresponsive to immunosuppressants. Approval was based on 2 phase 3 clinical studies. Both studies enrolled patients who had moderate-to-severe active ulcerative colitis despite concurrent or prior treatment with immunosuppressants (ie, corticosteroids, azathioprine, 6-mercaptopurine). Clinical remission was achieved in each study by week 8 and maintained in the long-term maintenance study at week 52.[60, 61]
Golimumab was approved for induction and maintenance of ulcerative colitis in May 2013. In the Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment (PURSUIT) trial, a significantly higher proportion of patients receiving induction treatment with subcutaneous administrations of golimumab 200 mg at week 0 and 100 mg at week 2, or golimumab 400 mg at week 0 and 200 mg at week 2, met the primary endpoint of clinical response at week 6 compared with the placebo (51.8%, 55%, and 29.7% of patients achieving clinical response, respectively [P < .0001]).
Some evidence suggests that in carefully selected patients who fail both steroids and either cyclosporine or infliximab, a crossover to the other of these second-line treatments may avoid colectomy in the short term (within 2 mo).
The long-term outcome in such patients is less clear, and further followup studies are required both to assess the frequency with which such rescued patients progress to colectomy and to compare overall outcomes in the longer term in such patients after crossover of second-line therapy compared with transition to colectomy after the first failure of second-line therapy.
Vedolizumab is a recombinant humanized monoclonal antibody that binds to α4β7 integrin. Integrins are proteins involved in regulating cellular movement including migration of leukocytes to the gut. Vedolizumab is indicated for moderate to severe ulcerative colitis in patients who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. Approval was based on a large phase 3 clinical trial conducted to simultaneously evaluate vedolizumab for both UC and Crohn disease, and included several clinical studies involving 2,700 patients in nearly 40 countries.
In patients with UC who had a response to vedolizumab induction, 41.8% continued to be in clinical remission at 52 weeks compared with 15.9% of patient taking placebo (P< 0.001).
For induction, other treatments have been proposed—but are not standard therapy—and include the following:
Antibiotics have been used as an adjunct to steroid therapy but have not altered outcomes. However, a systemic review and meta-analysis by Khan et al suggests that antibiotic therapy may induce remission in active ulcerative colitis. 
Helminth ova have not been shown to be superior to placebo.
Heparin may promote epithelial repair but is not effective given current delivery systems.
Leukocytapheresis has some promise and is quite popular in Japan, where it has been used to induce remission  and prevent postoperative septic complications.  Confirmatory studies in adults  and pediatric patients  are very promising. However, it remains a resource-intensive treatment.
Indications for Surgery
Historically, surgery has been viewed as definitive therapy for ulcerative colitis. Indications for surgery in ulcerative colitis are varied. Failure of medical management is the most common indication for surgery.
Indications for urgent surgery in patients with ulcerative colitis include (1) toxic megacolon refractory to medical management, (2) fulminant attack refractory to medical management, and (3) uncontrolled colonic bleeding. Indications for elective surgery in ulcerative colitis include (1) long-term steroid dependence, (2) dysplasia or adenocarcinoma found on screening biopsy, (3) and disease present for 7-10 years.
Once remission has been achieved, maintenance therapy is recommended for all patients to prevent relapse. Oral aminosalicylates are indicated for disease that responded to ASA or steroids. Patients who do not continue with maintenance therapy experience high rates of relapse. Some patients are unable to maintain remission or are intolerant of 5-ASA. Azathioprine and 6-mercaptopurine are alternatives with proven effectiveness. For patients who were induced with infliximab, maintenance therapy should continue with infliximab or azathioprine.
If golimumab was used for induction with a good response, monthly maintenance therapy should continue with golimumab. In the PURSUIT maintenance trial, patients responding to golimumab induction were randomized to receive golimumab or placebo for maintenance. Golimumab 100 mg SC q4wk maintained a clinical response through week 54 in 51% of patients compared with 31% of patient taking placebo (P < .001).
Corticosteroids may be used for induction of remission of active ulcerative colitis and continued for up to 8 weeks. A novel formulation of slow-release budesonide (Uceris) was approved by the FDA in January 2013. Approval was based on results from the CORE 1 study that showed endoscopic improvement at 8 weeks, increased remission rates, and clinical improvement with budesonide 9 mg once daily.
Probiotics also appear to be effective at maintaining remission. Escherichia coli strain Nissle 1917 has been compared with mesalazine and proved to be similarly effective. Bio-Three, a commercially available probiotic supplement (Enterococcus T-110, C butyricum TO-A, B mesentericus TO-A) produced remission in 45% of patients tested with mild-to-moderate ulcerative colitis. Trials of fish oil to produce or maintain remission have shown no benefit over placebo.
No specific diet restrictions are required for patients with ulcerative colitis. However, many patients with ulcerative colitis can have concurrent lactose intolerance. No specific diet can maintain remission.
Elemental nutrition and parenteral nutrition have no primary therapeutic role in ulcerative colitis, although parenteral nutrition is often used in patients who are severely ill as effective nutritional support.
Several complications have been reported after ileal pouch–anal anastomosis procedures. The anastomotic leak rate is 7-9%. If anastomotic leak occurs, fecal diversion, percutaneous drain placement, or repeat surgery with removal or revision of the reservoir is required. Pelvic abscess, which frequently accompanies an anastomotic leak, occurs in about 5% of cases (reports vary from 0-25%). Among patients with a pelvic abscess, 26% require excision of the pouch. Only 5.9% of patients without an abscess have pouch failure that requires removal.
If the abscess is managed with diversion and drainage, the pouch may be spared. However, these patients have higher rates of long-term incontinence and pain compared with those without abscesses. In patients who require pouch excision due to abscess, a gracilis muscle interposition flap has been used to maintain the anal canal and allow future attempts at pouch procedures. Pouch-vesicle, pouch-vaginal, pouch-anal, and enterocutaneous fistulas occur with a frequency of about 1% each.
Outcomes of pouch procedures are classified as good to excellent in as many as 90% of patients. Stool frequency is less than 5 per day in as many as 74%. Difficulty with evacuation occurs in 20%. About 77% of patients require no dietary restrictions; the remaining patients have a lower stool frequency with a low-fat diet. Complete incontinence is reported in only 2%. Bulk-forming agents are required in as many as 30%.
Sexual dysfunction, manifest by retrograde ejaculation or impotence, occurs in 3% of males. Although Meagher et al reported sexual dysfunction in only 6% of females, Ogilvie et al reported that 47% of females have low Female Sexual Function Index (FSFI) scores, indicating sexual dysfunction. Additionally, Cornish et al described a 25% incidence of sexual dysfunction manifested by dyspareunia or psychological aversion to intercourse for fear of stool leakage. The report also documented an increase in infertility from 8% preoperatively to 26% postoperatively.
Pouchitis is defined as a clinical syndrome in which the patient has increased stool frequency, malaise, fever, or incontinence. This syndrome usually responds to antibiotic therapy. The most frequently used antibiotics are ciprofloxacin or metronidazole. The incidence is reported to be 40-60%. Risk increases with time; 18% have pouchitis at 1 year, and 48% have pouchitis at 10 years. Pouch dilatation and pouch-anal anastomotic stricture may lead to fecal stasis and predispose the patient to pouchitis. Patients without a pouch rarely develop pouchitis and have comparable stool frequency with time. Clostridium difficile and Clostridium perfringens have been disproportionately found in patients with ulcerative colitis after ileal pouch–anal anastomosis. Treatment of these infections has led to decreases in inflammation.[81, 82]
Toxic megacolon occurs in less than 2% of cases and can be induced by hypokalemia, opiates, anticholinergics, and barium enemas. Patients are acutely ill. Conservative treatment can be tried for 24-48 hours with IV fluids, IV steroids, antibiotics, and IV cyclosporine. Patients may eventually require a total colectomy.
Carcinoma is a known complication of ulcerative colitis in the small group of patients who have had the disease for approximately 10 years. The cancer tends to be multicentric, atypical in its appearance, and rapidly metastasizing. The risk of colorectal cancer increases by 0.5-1% per year. Regular surveillance is needed.
Although the incidence of colon adenocarcinoma is greatly reduced with total proctocolectomy and ileal pouch–anal anastomosis, it is not zero. The residual colonic mucosa is at risk for dysplasia and neoplastic transformation.
Because of the increased risk of colorectal cancer, guidelines from the American College of Gastroenterology recommend that after 8-10 years of colitis, patients with ulcerative colitis should undergo annual or biannual surveillance colonoscopy with multiple biopsies at regular intervals. The finding of high-grade dysplasia in flat mucosa, confirmed on review by an expert pathologist, is an indication for colectomy; the finding of low-grade dysplasia in flat mucosa may also be an indication for colectomy to prevent progression to a higher grade of neoplasia.
In a study that aimed to identify a panel of markers associated with the long-term outcome of infliximab therapy for patients with refractory ulcerative colitis (median follow-up, 5 y), Arias et al confirmed that short-term clinical response and mucosal healing—as well as baseline levels of C-reactive protein (CRP) of 5 mg/L or less and albumin of 35 g/L or greater—were independent predictors of colectomy-free survival. Moreover, infliximab levels over 2.5 μg/mL at week 14 of treatment predicted both relapse- and colectomy-free survival. A combined risk panel that included clinical response, mucosal healing, and levels of pANCA, CRP, and albumin identified patients at risk for disease relapse or colectomy.
In patients with chronic pouch inflammation, villous hypertrophy and dysplasia may occur. Although dysplasia has never been found within the pouch of a pediatric patient, chronic inflammatory changes have been found, leading to the supposition that dysplasia may develop. Yearly screening endoscopy has been recommended for the first 5 years after the procedure. In children who have chronic inflammatory changes in the pouch reservoir, annual screening endoscopy should be performed. If no inflammation is present, screening endoscopy may be performed every 2 years.
Patients with extensive colitis or left-sided colitis with negative findings on screening colonoscopy should begin surveillance colonoscopy in 1-2 years. For patients with ulcerative colitis and primary sclerosing cholangitis, screening and subsequent surveillance colonoscopy should begin on an annual basis at the time of onset of primary sclerosing cholangitis.
Patients with proctosigmoiditis have no increased risk for colorectal cancer compared with the general population. However, these patients should be managed according to the current guidelines on colorectal cancer screening. If high-grade dysplasia or cancer is found, colectomy is performed. The management of low-grade dysplasia is controversial ; however, most experts would recommend colectomy.
Murata I, Satoh K, Yoshikawa I, Masumoto A, Sasaki E, Otsuki M. Recurrent subcutaneous abscess of the sternal region in ulcerative colitis. Am J Gastroenterol. 1999 Mar. 94(3):844-5. [Medline].
Kimura K, Hunter SF, Thollander MS, Loftus EV Jr, Melton LJ 3rd, O'Brien PC, et al. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc. 2000 Aug. 75(8):802-6. [Medline].
Egan CA, Meadows KP, Zone JJ. Ulcerative colitis and immunobullous disease cured by colectomy. Arch Dermatol. 1999 Feb. 135(2):214-5. [Medline].
Shen B. Crohn's disease of the ileal pouch: reality, diagnosis, and management. Inflamm Bowel Dis. 2009 Feb. 15(2):284-94. [Medline].
Heuschen UA, Hinz U, Allemeyer EH, Stern J, Lucas M, Autschbach F. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology. 2001 Mar. 120(4):841-7. [Medline].
Kaufman SS, Vanderhoof JA, Young R, Perry D, Raynor SC, Mack DR. Gastroenteric inflammation in children with ulcerative colitis. Am J Gastroenterol. 1997 Jul. 92(7):1209-12. [Medline].
Himmel ME, Hardenberg G, Piccirillo CA, Steiner TS, Levings MK. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology. 2008 Oct. 125(2):145-53. [Medline].
Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007 Jul 26. 448(7152):427-34. [Medline].
Lindberg E, Magnusson KE, Tysk C, Jarnerot G. Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. Gut. 1992 Jul. 33(7):909-13. [Medline]. [Full Text].
Barrett JC, Lee JC, Lees CW, Prescott NJ, Anderson CA, Phillips A, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet. 2009 Dec. 41(12):1330-4. [Medline]. [Full Text].
Vasiliauskas E. Serum immune markers in inflammatory bowel disease. Gastroenterology and Endoscopy News. Available at http://www.gastroendonews.com.
Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001 Mar. 96(3):730-4. [Medline].
Dubinsky MC, Ofman JJ, Urman M, Targan SR, Seidman EG. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2001 Mar. 96(3):758-65. [Medline].
Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for inflammatory bowel disease. J Pediatr. 1999 Apr. 134(4):447-52. [Medline].
Kaditis AG, Perrault J, Sandborn WJ, Landers CJ, Zinsmeister AR, Targan SR. Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr. 1998 Apr. 26(4):386-92. [Medline].
Duggan AE, Usmani I, Neal KR, Logan RF. Appendicectomy, childhood hygiene, Helicobacter pylori status, and risk of inflammatory bowel disease: a case control study. Gut. 1998 Oct. 43(4):494-8. [Medline]. [Full Text].
Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy and protection against ulcerative colitis. N Engl J Med. 2001 Mar 15. 344(11):808-14. [Medline].
Levenstein S, Prantera C, Varvo V, Scribano ML, Andreoli A, Luzi C, et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol. 2000 May. 95(5):1213-20. [Medline].
Almeida MG, Kiss DR, Zilberstein B, Quintanilha AG, Teixeira MG, Habr-Gama A. Intestinal mucosa-associated microflora in ulcerative colitis patients before and after restorative proctocolectomy with an ileoanal pouch. Dis Colon Rectum. 2008 Jul. 51(7):1113-9. [Medline].
Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2000 Aug. 95(8):1949-54. [Medline].
Bousvaros A, Zurakowski D, Duggan C, Law T, Rifai N, Goldberg NE, et al. Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. J Pediatr Gastroenterol Nutr. 1998 Feb. 26(2):129-35. [Medline].
Garland CF, Lilienfeld AM, Mendeloff AI, Markowitz JA, Terrell KB, Garland FC. Incidence rates of ulcerative colitis and Crohn's disease in fifteen areas of the United States. Gastroenterology. 1981 Dec. 81(6):1115-24. [Medline].
Cotran RS, Collins T, Robbins SL, Kumar V. Pathologic Basis of Disease. Philadelphia, Pa: WB Saunders; 1998.
Jang ES, Lee DH, Kim J, Yang HJ, Lee SH, Park YS. Age as a clinical predictor of relapse after induction therapy in ulcerative colitis. Hepatogastroenterology. 2009 Sep-Oct. 56(94-95):1304-9. [Medline].
Gooding IR, Springall R, Talbot IC, Silk DB. Idiopathic small-intestinal inflammation after colectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 2008 Jun. 6(6):707-9. [Medline].
Slatter C, Girgis S, Huynh H, El-Matary W. Pre-pouch ileitis after colectomy in paediatric ulcerative colitis. Acta Paediatr. 2008 Mar. 97(3):381-3. [Medline].
Falcone RA Jr, Lewis LG, Warner BW. Predicting the need for colectomy in pediatric patients with ulcerative colitis. J Gastrointest Surg. 2000 Mar-Apr. 4(2):201-6. [Medline].
Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun 30. 330(26):1841-5. [Medline].
Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol. 2000 Aug. 95(8):2000-8. [Medline].
Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001 Apr. 96(4):1116-22. [Medline].
de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol. 2000 Dec. 27(12):2860-5. [Medline].
Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998 Nov. 27(5):580-3. [Medline].
Marchesa P, Lashner BA, Lavery IC, Milsom J, Hull TL, Strong SA. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1997 Aug. 92(8):1285-8. [Medline].
Kim B, Barnett JL, Kleer CG, Appelman HD. Endoscopic and histological patchiness in treated ulcerative colitis. Am J Gastroenterol. 1999 Nov. 94(11):3258-62. [Medline].
Calabrese C, Fabbri A, Gionchetti P, Rizzello F, Morselli C, Liguori G, et al. Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis. Aliment Pharmacol Ther. 2007 Jun 1. 25(11):1311-6. [Medline].
Carucci LR, Levine MS. Radiographic imaging of inflammatory bowel disease. Gastroenterol Clin North Am. 2002 Mar. 31(1):93-117, ix. [Medline].
Eisenberg RL. Gastrointestinal Radiology: A Pattern Approach. Philadelphia, Pa: Lippincott-Raven; 1998. 602-8.
Wiesner W, Steinbrich W. [Imaging diagnosis of inflammatory bowel disease]. Ther Umsch. 2003 Mar. 60(3):137-44. [Medline].
van den Broek FJ, Fockens P, Dekker E. Review article: New developments in colonic imaging. Aliment Pharmacol Ther. 2007 Dec. 26 Suppl 2:91-9. [Medline].
Deutsch DE, Olson AD. Colonoscopy or sigmoidoscopy as the initial evaluation of pediatric patients with colitis: a survey of physician behavior and a cost analysis. J Pediatr Gastroenterol Nutr. 1997 Jul. 25(1):26-31. [Medline].
Matsumoto T, Nakamura S, Jin-No Y, Sawa Y, Hara J, Oshitani N, et al. Role of granuloma in the immunopathogenesis of Crohn's disease. Digestion. 2001. 63 Suppl 1:43-7. [Medline].
Basson MD, Etter L, Panzini LA. Rates of colonoscopic perforation in current practice. Gastroenterology. 1998 May. 114(5):1115. [Medline].
Polter DE. Risk of colon perforation during colonoscopy at Baylor University Medical Center. Proc (Bayl Univ Med Cent). 2015 Jan. 28(1):3-6. [Medline].
Makkar R, Bo S. Colonoscopic perforation in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2013 Sep. 9(9):573-83. [Medline].
[Guideline] Leighton JA, Shen B, Baron TH, Adler DG, Davila R, Egan JV, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc. 2006 Apr. 63(4):558-65. [Medline].
Ford AC, Achkar JP, Khan KJ, Kane SV, Talley NJ, Marshall JK, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr. 106(4):601-16. [Medline].
Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011 Mar. 33(6):672-8. [Medline].
Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol. 2007 Dec. 21(12):827-34. [Medline].
Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009 Dec. 137(6):1934-43.e1-3. [Medline].
Ford AC, Khan KJ, Sandborn WJ, Kane SV, Moayyedi P. Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2011 Dec. 106(12):2070-7. [Medline].
D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P. Once-Daily MMX® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis. Am J Gastroenterol. 2012 May 8. [Medline].
Barber J Jr. FDA approves Uceris for ulcerative colitis. Medscape Medical News. Jan 18, 2013. Available at http://www.medscape.com/viewarticle/777917. Accessed: January 28, 2013.
Sandborn WJ, Danese S, D'Haens G, et al. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther. 2015 Mar. 41 (5):409-18. [Medline].
Uceris Rectal Foam (budesonide [package insert]. Raleigh, NC 27615: Distributed by Salix Pharmaceuticals, Inc. (under license from Dr. Falk Pharma). October 8, 2014. Available at [Full Text].
Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr. 106(4):590-9. [Medline].
Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr. 106(4):644-59, quiz 660. [Medline].
Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct. 137(4):1250-60; quiz 1520. [Medline].
Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun. 60(6):780-7. [Medline].
Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb. 142(2):257-65.e1-3. [Medline].
Sandborn WJ, et al. A phase 2/3 randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of subcutaneous golimumab induction therapy in patients with moderately to severely active ulcerative colitis (UC): Pursuit SC (Abstract #943d) Presented at Digestive Disease Week, May 21, 2012 San Diego, CA.
Leblanc S, Allez M, Seksik P, Flourié B, Peeters H, Dupas JL, et al. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2011 Apr. 106(4):771-7. [Medline].
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22. 369(8):699-710. [Medline].
Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr. 106(4):661-73. [Medline].
Sakuraba A, Sato T, Naganuma M, Morohoshi Y, Matsuoka K, Inoue N, et al. A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis. J Gastroenterol. 2008. 43(1):51-6. [Medline].
Miki C, Okita Y, Yoshiyama S, Araki T, Uchida K, Kusunoki M. Early postoperative application of extracorporeal leukocyte apheresis in ulcerative colitis patients: results of a pilot trial to prevent postoperative septic complications. J Gastroenterol. 2007 Jun. 42(6):508-9. [Medline].
Emmrich J, Petermann S, Nowak D, Beutner I, Brock P, Klingel R, et al. Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis--results of a randomized pilot trial. Dig Dis Sci. 2007 Sep. 52(9):2044-53. [Medline].
Ruuska T, Lahdeaho ML, Sutas Y, Ashorn M, Grönlund J. Leucocyte apheresis in the treatment of paediatric ulcerative colitis. Scand J Gastroenterol. 2007 Nov. 42(11):1390-1. [Medline].
Sandborn WJ, et al. A phase III randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of subcutaneous golimumab maintenance therapy in patients with moderately to severely active ulcerative colitis: PURSUIT-Maintenance. Presented at the American College of Gastroenterology, October 22, 2012 Las Vegas, NV.
Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012 Nov. 143(5):1218-26.e1-2. [Medline].
Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999 Aug 21. 354(9179):635-9. [Medline].
Tsuda Y, Yoshimatsu Y, Aoki H, Nakamura K, Irie M, Fukuda K. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol. 2007 Nov. 42(11):1306-11. [Medline].
Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg. 2000 Jul. 24(7):851-6. [Medline].
Farouk R, Dozois RR, Pemberton JH, Larson D. Incidence and subsequent impact of pelvic abscess after ileal pouch-anal anastomosis for chronic ulcerative colitis. Dis Colon Rectum. 1998 Oct. 41(10):1239-43. [Medline].
Shamberger RC, Hergrueter CA, Lillehei CW. Use of a gracilis muscle flap to facilitate delayed ileal pouch-anal anastomosis. Dis Colon Rectum. 2000 Nov. 43(11):1628-31. [Medline].
Karlbom U, Raab Y, Ejerblad S, Graf W, Thörn M, Pâhlman L. Factors influencing the functional outcome of restorative proctocolectomy in ulcerative colitis. Br J Surg. 2000 Oct. 87(10):1401-8. [Medline].
Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998 Jun. 85(6):800-3. [Medline].
Ogilvie JW Jr, Goetz L, Baxter NN, Park J, Minami S, Madoff RD. Female sexual dysfunction after ileal pouch-anal anastomosis. Br J Surg. 2008 Jul. 95(7):887-92. [Medline].
Cornish JA, Tan E, Teare J, Teoh TG, Rai R, Darzi AW. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum. 2007 Aug. 50(8):1128-38. [Medline].
Shen BO, Jiang ZD, Fazio VW, Remzi FH, Rodriguez L, Bennett AE. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008 Jul. 6(7):782-8. [Medline].
Falk A, Olsson C, Ahrné S, Molin G, Adawi D, Jeppsson B. Ileal pelvic pouch microbiota from two former ulcerative colitis patients, analysed by DNA-based methods, were unstable over time and showed the presence of Clostridium perfringens. Scand J Gastroenterol. 2007 Aug. 42(8):973-85. [Medline].
Chia CS, Chew MH, Chau YP, Eu KW, Ho KS. Adenocarcinoma of the anal transitional zone after double stapled ileal pouch-anal anastomosis for ulcerative colitis. Colorectal Dis. 2008 Jul. 10(6):621-3. [Medline].
Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010 Mar. 105(3):501-23; quiz 524. [Medline].
Arias MT, Vande Casteele N, Vermeire S, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015 Mar. 13 (3):531-8. [Medline].
Sarigol S, Wyllie R, Gramlich T, Alexander F, Fazio V, Kay M, et al. Incidence of dysplasia in pelvic pouches in pediatric patients after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr. 1999 Apr. 28(4):429-34. [Medline].
Pekow JR, Hetzel JT, Rothe JA, Hanauer SB, Turner JR, Hart J. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010 Aug. 16(8):1352-6. [Medline].
Parente F, Molteni M, Marino B, Colli A, Ardizzone S, Greco S, et al. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis?: a prospective study. Am J Gastroenterol. 2010 May. 105(5):1150-7. [Medline].
Andersson T, Lunde OC, Johnson E, Moum T, Nesbakken A. Long-term functional outcome and quality of life after restorative proctocolectomy with ileo-anal anastomosis for colitis. Colorectal Dis. 2009 Dec 14. [Medline].
Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010 Jan. 16(1):112-24. [Medline].
Brooks M. FDA approves new indication for Simponi. Medscape Medical News. May 15, 2013. [Full Text].
Charron M, del Rosario JF, Kocoshis S. Use of technetium-tagged white blood cells in patients with Crohn's disease and ulcerative colitis: is differential diagnosis possible?. Pediatr Radiol. 1998 Nov. 28(11):871-7. [Medline].
Choi JS, Potenti F, Wexner SD, Nam YS, Hwang YH, Nogueras JJ, et al. Functional outcomes in patients with mucosal ulcerative colitis after ileal pouch-anal anastomosis by the double stapling technique: is there a relation to tissue type?. Dis Colon Rectum. 2000 Oct. 43(10):1398-404. [Medline].
Cottliar A, Fundia A, Boerr L, Sambuelli A, Negreira S, Gil A, et al. High frequencies of telomeric associations, chromosome aberrations, and sister chromatid exchanges in ulcerative colitis. Am J Gastroenterol. 2000 Sep. 95(9):2301-7. [Medline].
Cucchiara S, Celentano L, de Magistris TM, Montisci A, Iula VD, Fecarotta S. Colonoscopy and technetium-99m white cell scan in children with suspected inflammatory bowel disease. J Pediatr. 1999 Dec. 135(6):727-32. [Medline].
da Luz Moreira A, Kiran RP, Lavery I. Clinical outcomes of ileorectal anastomosis for ulcerative colitis. Br J Surg. 2010 Jan. 97(1):65-9. [Medline].
Durno C, Sherman P, Harris K, Smith C, Dupuis A, Shandling B, et al. Outcome after ileoanal anastomosis in pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr. 1998 Nov. 27(5):501-7. [Medline].
Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990 Nov 1. 323(18):1228-33. [Medline].
Fonkalsrud EW, Thakur A, Roof L. Comparison of loop versus end ileostomy for fecal diversion after restorative proctocolectomy for ulcerative colitis. J Am Coll Surg. 2000 Apr. 190(4):418-22. [Medline].
Gorfine SR, Bauer JJ, Harris MT, Kreel I. Dysplasia complicating chronic ulcerative colitis: is immediate colectomy warranted?. Dis Colon Rectum. 2000 Nov. 43(11):1575-81. [Medline].
Hunt LE, Eichenberger MR, Petras R, Galandiuk S. Use of a microsatellite marker in predicting dysplasia in ulcerative colitis. Arch Surg. 2000 May. 135(5):582-5. [Medline].
Metcalf DR, Nivatvongs S, Sullivan TM, Suwanthanma W. A technique of extending small-bowel mesentery for ileal pouch-anal anastomosis: report of a case. Dis Colon Rectum. 2008 Mar. 51(3):363-4. [Medline].
Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006 Apr. 130(4):1030-8. [Medline].
Shamberger RC, Masek BJ, Leichtner AM, Winter HS, Lillehei CW. Quality-of-life assessment after ileoanal pull-through for ulcerative colitis and familial adenomatous polyposis. J Pediatr Surg. 1999 Jan. 34(1):163-6. [Medline].
Treem WR, Cohen J, Davis PM, Justinich CJ, Hyams JS. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum. 1995 May. 38(5):474-9. [Medline].
|Ulcerative Colitis||Crohn Disease|
|Only colon involved||Panintestinal|
|Continuous inflammation extending proximally from rectum||Skip-lesions with intervening normal mucosa|
|Inflammation in mucosa and submucosa only||Transmural inflammation|
|No granulomas||Noncaseating granulomas|
|Perinuclear ANCA (pANCA) positive||ASCA positive|
|Bleeding (common)||Bleeding (uncommon)|
|Fistulae (rare)||Fistulae (common)|